Treatment of pancreatitis with amylin

• US 8,168,233 B2
• Filed: 09/24/2003
• Issued: 05/01/2012
• Est. Priority Date: 10/18/2002
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Gedulin, Bronislava, Young, Andrew A.
• Primary Examiner(s): Tate, Christopher R
• Assistant Examiner(s): WINSTON, RANDALL O
• Application Number:
  US10/671,304
• Publication Number:
  US 20050070472A1
• Time in Patent Office: 3,142 Days
• Field of Search: 514/12
• US Class Current: 424/725
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35

Abstract

The disclosed invention provides for the treatment of pancreatitis, and the alleviation of pain associated therewith, with amylin, amylin agonists and amylin analogs.

Claims

1. A method of treating pancreatitis in a mammalian subject afflicted with pancreatitis comprising

administering to said subject an effective amount of an amylin or an amylin analog, wherein the amylin analog has amylin agonist activity,

wherein the level of enzymatic activity and/or enzymatic secretion in pancreatic cells of said subject is reduced or inhibited.

2. The method of claim 1 wherein said subject is a human.

3. The method of claim 1 wherein said amylin analog is ^25,28,29Pro-h-amylin.

4. The method of claim 1 wherein 0.1 μ

g to 1 mg of said amylin or said amylin analog is administered to said mammalian subject in a single, divided, or continuous dose.

5. The method of claim 1 wherein about 2 μ

g to about 8 mg per day of said amylin or said amylin analog is administered to said mammalian subject.

6. The method of claim 1 wherein the amylin or amylin analog is amylin.

7. The method of claim 1 wherein the pancreatitis is acute pancreatitis.

8. The method of claim 1 wherein the pancreatitis is chronic pancreatitis.

9. The method of claim 7 further comprising administering to the subject an agent or regimen used to treat acute pancreatitis.

10. The method of claim 9 wherein the agent is clinically used to treat pancreatitis.

11. The method of claim 9 wherein the agent is a pancreatic enzyme.

12. The method of claim 9 wherein the regime includes a low-fat diet.

13. The method of claim 9 further comprising administering to said subject an analgesic.